NIRVF (Nirvana Life Sciences) Non Operating Income: $0.01 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nirvana Life Sciences Non Operating Income?

Nirvana Life Sciences NIRVF Non Operating Income is $0.01 Mil as of Jan. 2026. The stock has 3 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Nirvana Life Sciences's Non Operating Income for the six months ended in Jan. 2026 was $0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jan. 2026 was $0.01 Mil.

Nirvana Life Sciences Non Operating Income Related Terms

Nirvana Life Sciences Non Operating Income Historical Data

* Premium members only.

The historical data trend for Nirvana Life Sciences's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nirvana Life Sciences Non Operating Income Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23 Apr24 Apr25
Non Operating Income
Get a 7-Day Free Trial 0.06 -3.56 -0.17 -0.09 0.00

Nirvana Life Sciences Semi-Annual Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.01 0.00 0.00

Nirvana Life Sciences Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Non Operating Income for the trailing twelve months (TTM) ended in Jan. 2026 was $0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $0.01 Mil mean?
Nirvana Life Sciences (NIRVF) has a Non Operating Income of $0.01 Mil as of Jan. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Nirvana Life Sciences and its competitors.
Is Nirvana Life Sciences' Non Operating Income too high?
Nirvana Life Sciences' current Non Operating Income is $0.01 Mil.
How does Nirvana Life Sciences' Non Operating Income compare to VRTX and REGN?
Nirvana Life Sciences' Non Operating Income of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Nirvana Life Sciences and its competitors. Nirvana Life Sciences's current Non Operating Income is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nirvana Life Sciences stock overvalued right now?
Nirvana Life Sciences (NIRVF) has a current Non Operating Income of $0.01 Mil. The current Non Operating Income is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Nirvana Life Sciences (NIRVF), the current Non Operating Income is $0.01 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nirvana Life Sciences Business Description

Other Exchanges NIRV.X:Canada
Address 650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc. is a Canadian life sciences company focused on research and development of therapeutic products derived from psychedelic compounds. It works on novel formulations of psilocybin and other naturally sourced psychedelics, targeting indications such as chronic pain, opioid dependency, and other health conditions. The company also develops methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds, aiming to support consistent dosing and regulatory compliance. It operates in a single reportable segment, the research and development of psychedelic-derived therapeutics, and is based in Canada. As a development-stage enterprise, it does not yet generate meaningful product revenue; its activities are funded through equity financing and similar sources while it advances preclinical research and formulation work. Its primary stakeholders are investors and research collaborators rather than commercial customers.